Heart Failure and Diabetes Mellitus: Biomarkers in Risk Stratification and Prognostication

Heart Failure and Diabetes Mellitus: Biomarkers in Risk Stratification and Prognostication

Heart failure (HF) and type 2 diabetes mellitus (T2DM) have a synergistic effect on cardiovascular (CV) morbidity and mortality in patients with established CV disease (CVD). The aim of this review is to summarize the knowledge regarding the discriminative abilities of conventional and novel biomark...

Full description

Bibliographic Details
Main Authors:	Michael Lichtenauer, Peter Jirak, Vera Paar, Brigitte Sipos, Kristen Kopp, Alexander E. Berezin
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Series:	Applied Sciences
Subjects:	heart failure heart failure with reduced ejection fraction heart failure with preserved ejection fraction diabetes mellitus circulating biomarkers prognosis
Online Access:	https://www.mdpi.com/2076-3417/11/10/4397

Similar Items

Discriminative Value of Serum Irisin in Prediction of Heart Failure with Different Phenotypes among Patients with Type 2 Diabetes Mellitus
by: Alexander A. Berezin, et al.
Published: (2022-09-01)

Gender‐specific risks for incident cancer in patients with different heart failure phenotypes
by: Qin‐Fen Chen, et al.
Published: (2025-02-01)

Interpretation of the Essential Updates in 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
by: Yifang GUO
Published: (2022-06-01)

Sirt1 Activity in PBMCs as a Biomarker of Different Heart Failure Phenotypes
by: Valeria Conti, et al.
Published: (2020-11-01)

Trajectory of Irisin as a Predictor of Kidney-Related Outcomes in Patients with Asymptomatic Heart Failure
by: Tetiana A. Berezina, et al.
Published: (2024-08-01)

Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study
by: Eiichi Akiyama, et al.
Published: (2020-06-01)

Circulating Cell-Free Nuclear DNA Predicted an Improvement of Systolic Left Ventricular Function in Individuals with Chronic Heart Failure with Reduced Ejection Fraction
by: Tetiana Berezina, et al.
Published: (2024-10-01)

Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction
by: Federico Ferro, et al.
Published: (2022-07-01)

Sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: A review
by: Igor V. Zhirov, et al.
Published: (2023-11-01)

Impact of Obstructive Sleep Apnea in Patients with Acute Heart Failure: A Nationwide Cohort Study
by: Abdulmajeed Alharbi, et al.
Published: (2024-11-01)

Association of Depression and Anxiety with Cardiac Structural and Functional Characteristics in Heart Failure with Reduced and Mildly Reduced Ejection Fraction
by: Timea Magdolna Szabo, et al.
Published: (2023-03-01)

Metabolomics and a Breath Sensor Identify Acetone as a Biomarker for Heart Failure
by: Patrick A. Gladding, et al.
Published: (2022-12-01)

Pharmacological and Non-Pharmacological Advancements in Heart Failure Treatment
by: Chen Wang, et al.
Published: (2024-06-01)

Magnesium, Oxidative Stress, Inflammation, and Cardiovascular Disease
by: Man Liu, et al.
Published: (2020-09-01)

IL‐6 and hsCRP predict cardiovascular mortality in patients with heart failure with preserved ejection fraction
by: Martin Berger, et al.
Published: (2024-12-01)

Cardiovascular magnetic resonance assessment of coronary flow reserve improves risk stratification in heart failure with preserved ejection fraction
by: Shingo Kato, et al.
Published: (2021-10-01)

Correlation of β-adrenergic reactivity of erythrocyte membranes with clinical characteristics of patients with coronary artery disease and HF with preserved and reduced ejection fraction
by: E. F. Muslimova, et al.
Published: (2025-01-01)

Prognostic significance of NT-proBNP and sST2 in patients with heart failure with preserved and mildly reduced ejection fraction
by: V. I. Podzolkov, et al.
Published: (2023-10-01)

The Impact of Specialised Heart Failure Outpatient Care on the Long-Term Application of Guideline-Directed Medical Therapy and on Prognosis in Heart Failure with Reduced Ejection Fraction
by: Balázs Muk, et al.
Published: (2024-01-01)

Summary and Comparison of the 2022 ACC/AHA/HFSA and 2021 ESC Heart Failure Guidelines
by: Sarah Badger, et al.
Published: (2023-08-01)

Prognostic Value of Epicardial Adipose Tissue in Heart Failure With Mid‐Range and Preserved Ejection Fraction: A Multicenter Study
by: Wenxian Wang, et al.
Published: (2024-12-01)

Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding
by: Steven J. Simmonds, et al.
Published: (2020-01-01)

Left Ventricular Ejection Fraction in Heart Failure: Crazy, Stupid Love—and Maybe, Redemption
by: Milton Packer
Published: (2024-04-01)

Phenotypic clusters in heart failure with preserved and mid-range ejection fraction: new data and perspectives
by: O. V. Tsygankova, et al.
Published: (2021-05-01)

Heart failure with preserved ejection fraction – new elements of evidence in the field of pathophysiology and new treatment options
by: Branimir Kanazirev
Published: (2021-07-01)

Prognostic value of growth differentiation factor‐15 in heart failure among whole ejection fraction phenotypes
by: Lyu Lyu, et al.
Published: (2024-08-01)

Cardiac magnetic resonance left ventricular filling pressure is linked to symptoms, signs and prognosis in heart failure
by: Ciaran Grafton‐Clarke, et al.
Published: (2023-10-01)

New possibilities in pharmacotherapy for the heart failure with reduced ejection fraction treatment in patients with recent deterioration
by: I. V. Gribkova
Published: (2024-03-01)

Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction
by: Luigi Falco, et al.
Published: (2023-09-01)

Mean platelet volume: a prognostic marker in heart failure with preserved ejection fraction
by: Nassiba Menghoum, et al.
Published: (2023-12-01)

Characteristics, outcomes and the necessity of continued guideline-directed medical therapy in patients with heart failure with improved ejection fraction
by: Qin-Fen Chen, et al.
Published: (2025-12-01)

Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction
by: Pushpraj Patel, et al.
Published: (2024-12-01)

The E/e’ Ratio—Role in Risk Stratification of Acute Heart Failure with Preserved Ejection Fraction
by: Marilena-Brîndușa Zamfirescu, et al.
Published: (2021-04-01)

Heart failure with preserved ejection fraction – onset
by: Branimir Kanazirev
Published: (2021-07-01)

Effects of different sodium–glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a network meta-analysis
by: Xiaohua Lan, et al.
Published: (2024-05-01)

Clinical and prognostic value of determining the level of neopterin in patients with chronic heart failure with preserved ejection fraction
by: O. S. Polunina, et al.
Published: (2018-10-01)

Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction
by: Shunsuke Kiuchi, et al.
Published: (2020-02-01)

Comparing outcomes after pulmonary vein isolation in patients with systolic and diastolic heart failure
by: Ahmad B. Allaw, MD, et al.
Published: (2024-08-01)

Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013–2021
by: Jimmy Gonzalez, et al.
Published: (2024-05-01)

Inhaled nitric oxide testing in predicting prognosis in pulmonary hypertension due to left‐sided heart diseases
by: Taijyu Satoh, et al.
Published: (2023-12-01)